1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Gan & Lee Pharmaceuticals.
  6. News
  7. Summary
    603087   CNE100003ZH1

GAN & LEE PHARMACEUTICALS.

(603087)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

12/06/2021 | 02:18pm EDT

Gan & Lee Pharmaceuticals Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company's compound, GZR18, to improve the management of type 2 diabetes mellitus. The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects such as the stimulation of insulin secretion and the inhibition of glucagon, when blood glucose is high.


© S&P Capital IQ 2021
All news about GAN & LEE PHARMACEUTICALS.
04/27Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 3..
CI
03/10Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug,..
AQ
03/10Gan & Lee Pharmaceuticals. Begins First-In-Human Trial in U.S. for Investigational Drug..
CI
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New..
CI
2021China’s Drug Procurement Program Cuts Insulin Costs by Around 48%
MT
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September..
CI
2021GAN & LEE PHARMACEUTICALS : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GL..
AQ
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2021GAN & LEE PHARMACEUTICALS : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Asp..
AQ
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results a..
CI
More news
Financials
Sales 2022 4 002 M 598 M 598 M
Net income 2022 1 533 M 229 M 229 M
Net Debt 2022 - - -
P/E ratio 2022 15,0x
Yield 2022 -
Capitalization 23 023 M 3 440 M 3 440 M
Capi. / Sales 2022 5,75x
Capi. / Sales 2023 4,75x
Nbr of Employees 3 278
Free-Float -
Chart GAN & LEE PHARMACEUTICALS.
Duration : Period :
Gan & Lee Pharmaceuticals. Technical Analysis Chart | 603087 | CNE100003ZH1 | MarketScreener
Technical analysis trends GAN & LEE PHARMACEUTICALS.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 41,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Zhong Ru Gan Chairman
Yan Sun Independent Director
Yan Qing He Independent Director
Guo Jun Zheng Independent Director
Kai Du Director & Director-International Department
Sector and Competitors
1st jan.Capi. (M$)
GAN & LEE PHARMACEUTICALS.-41.71%3 414
CSL LIMITED-5.70%93 360
SAMSUNG BIOLOGICS CO.,LTD.-7.97%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.05%21 450